Other three validated AML-PDX models, AM8096 (M2 subtype with RUNX1-RUNX1T1 fusion and CEBPA mutation), AM5512 (M7 subtype) and AM7407 (M4 subtype with KMT2A rearrangement) (Supplement Table S1) are also similarly suitable for pharmacology modeling. Here, CEBPA is linked to acute myeloid leukemia.